Regeneron Pharmaceuticals (REGN) Q4 2025 (USD): Adj. EPS 11.44 (exp. 10.56), Revenue 3.88bln (exp. 3.78bln)

Regeneron Pharmaceuticals reported stronger-than-expected Q4 2025 results, with adjusted EPS surpassing expectations and revenue also above consensus.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

EMA CHMP has recommended the following for approval: Fylrevy, Ilumira, Kayshild, Kygevvi, Supemtek & Rezurock.

Iranian Foreign Minister Araqchi says they are prepared to return to talks with the US, on the condition they are based on mutual respect. The US' attitude is contradictory. Not seeking nuclear weapons.

Regeneron Pharmaceuticals (REGN) Q4 2025 (USD): Adj. EPS 11.44 (exp. 10.56), Revenue 3.88bln (exp. 3.78bln)

Israel announces Rafah crossing to open this weekend amid ongoing EU discussions

Chevron will not increase capex this year to fast-track expansion in Venezuela, according to the FT citing the CFO

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This beat could enhance investor sentiment, particularly in the biotech sector, indicating robust demand for their products. Given the positive results, expect potential upward revisions in earnings estimates and a favorable impact on the stock and sector performance.

Related headlines

The whole workspace, free to try.

Try it free